Edition:
United Kingdom

ESSA Pharma Inc (EPIX.OQ)

EPIX.OQ on NASDAQ Stock Exchange Capital Market

0.22USD
17 Jan 2018
Change (% chg)

$0.01 (+7.14%)
Prev Close
$0.21
Open
$0.21
Day's High
$0.23
Day's Low
$0.21
Volume
206,564
Avg. Vol
37,514
52-wk High
$3.59
52-wk Low
$0.16

Chart for

About

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen... (more)

Overall

Beta: --
Market Cap(Mil.): $10.60
Shares Outstanding(Mil.): 29.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Bvf Partners Reports 9.9 Percent Passive Stake In Essa Pharma‍​

* BVF PARTNERS L.P REPORTS 9.9 PERCENT PASSIVE STAKE IN ESSA PHARMA INC AS OF JANUARY 5, 2018 - SEC FILING ‍​ Source text - http://bit.ly/2DgNTLE Further company coverage:

16 Jan 2018

BRIEF-Essa Says Intends To Issue Up To 125 Mln Common Shares At $0.20 Per Share

* ESSA ANNOUNCES FILING OF AMENDED AND RESTATED PROSPECTUS SUPPLEMENT AND AN UPDATE TO PREVIOUSLY ANNOUNCED EQUITY OFFERING

03 Jan 2018

BRIEF-Essa Pharma Announces Pricing Of Previously Announced Equity Offering

* ESSA PHARMA ANNOUNCES PRICING OF PREVIOUSLY ANNOUNCED EQUITY OFFERING

13 Dec 2017

BRIEF-ESSA Pharma announces overnight marketed equity offering

* ESSA PHARMA - TO USE NET PROCEEDS OF OFFERING PRIMARILY TO CONTINUE ONGOING PRECLINICAL DEVELOPMENT OF CO'S ANITEN COMPOUNDS Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Essa Pharma Reports Qtrly Loss Per Share Of $0.07

* ESSA PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FOURTH QUARTER AND YEAR ENDED SEPTEMBER 30, 2017

12 Dec 2017

Earnings vs. Estimates